The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary

Surgical Infections

Volumn 3, Issue 3, 2002, Pages 161-173

  Mazuski, John E ^a   Sawyer, Robert G ^b   Nathens, Avery B ^c   Dipiro, Joseph T ^d   Schein, Mosche ^e   Kudsk, Kenneth A ^f   Yowler, Charles ^g  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

^e BRONX LEBANON HOSPITAL CENTER   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; ERTAPENEM; FLUCONAZOLE; GENTAMICIN; MEROPENEM; METRONIDAZOLE; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG;

ABDOMINAL INFECTION; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLISHING; REVIEW; RISK ASSESSMENT; SURGICAL INFECTION;

EID: 0036763320     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/109629602761624171     Document Type: Review

References (96)

1. Bohnen JMA, Solomkin JS, Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992;127:83-89.
2. Pasquale, MD. Practice management guidelines for trauma [On-line]. Trauma Practice Guidelines. Available: www.east.org, 1998.
3. Wolfe BM, Mathiesen KA. Clinical practice guidelines in nutrition support: can they be based on randomized clinical trials? JPEN 1997;21:1-6.
4. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect 2002; 3:175-233.
5. Fabian TC, Croce MA, Payne LW, et al. Duration of antibiotic therapy for penetrating abdominal trauma: a prospective trial. Surgery 1992;112:788-795.
6. Bozorgzadeh A, Pizzi WF, Barie PS, et al. The duration of antibiotic administration in penetrating abdominal trauma. Am J Surg 1999;177:125-131.
7. Kirton OC, O'Neill PA, Kestner M, et al. Perioperative antibiotic use in high-risk penetrating hollow viscus injury: a prospective randomized, double-blind, placebo-control trial of 24 hours versus 5 days. J Trauma 2000;49:822-832.
8. Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. Br J Surg 1994;81:989-991.
9. Andåker L, Höjer H, Kihlström E, et al. Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Metronidazole-fosfomycin vs. metronidazole-gentamicin in 381 patients. Acta Chir Scand 1987;153:185-192.
10. Wittmann DH, Schein M. Let us shorten antibiotic prophylaxis and therapy in surgery. Am J Surg 1996;172:26S-32S.
11. Lennard ES, Minshew BH, Dellinger EP, et al. Leukocytosis at termination of antibiotic therapy: its importance for intra-abdominal sepsis. Arch Surg 1980;115:918-921.
12. Lennard ES, Dellinger EP, Wertz MJ, et al. Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann Surg 1982;195:19-24.
13. Smith JA, Bell GA, Murphy J, et al. Evaluation of the use of a protocol in the antimicrobial treatment of intra-abdominal sepsis. J Hosp Infect 1985;6:60-64.
14. Taylor E, Dev V, Shah D, et al. Complicated appendicitis: is there a minimum intravenous antibiotic requirement? A prospective randomized trial. Am Surg 2000;66:887-890.
15. Visser MR, Bosscha K, Olsman J, et al. Predictors of recurrence of fulminant bacterial peritonitis after discontinuation of antibiotics in open management of the abdomen. Eur J Surg 1998;164:825-829.
16. Malangoni MA, Condon RE, Spiegel CA. Treatment of intra-abdominal infections is appropriate with single-agent or combination antibiotic therapy. Surgery 1985;98:648-655.
17. Yellin AE, Heseltine PNR, Berne TV, et al. The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985;161:303-307.
18. Study Group of Intraabdominal Infections. A randomized controlled trial of ampicillin plus sulbactam vs. gentamicin plus clindamycin in the treatment of intraabdominal infections. A preliminary report. Rev Infect Dis 1986;8:S583-S588.
19. Lewis RT, Duma RJ, Echols RM, et al. Comparative study of cefotetan and cefoxitin in the treatment of intra-abdominal infections. Am J Obstet Gynecol 1988; 158:728-735.
20. Wilson SE, Boswick JA Jr, Duma RJ, et al. Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin. Am J Surg 1988; 155:61-66.
21. Holloway WJ, Winslow DL, Reinhardt JF. Cefmetazole treatment of intra-abdominal infection. J Antimicrob Chemother 1989;23(Suppl D):47-54.
22. Anonymous. A randomized multicentre trial of pefloxacin plus metronidazole and gentamicin plus metronidazole in the treatment of severe intra-abdominal infections. Reports from a Swedish Study Group. J Antimicrob Chemother 1990;26(Suppl B): 173-180.
23. Bubrick MP, Heim-Duthoy KL, Yellin AE, et al. Ceftazidime/clindamycin versus tobramycin/clindamycin in the treatment of intra-abdominal infections. Am Surg 1990;56:613-617.
24. Jauregui LE, Appelbaum PC, Fabian TC, et al. A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1990;25:423-433.
25. Kooi GH, Pit S. Ceftazidime/metronidazole versus netilmicin/metronidazole in the treatment of perforated appendicitis in children. Clin Ther 1990;12:54-60.
26. Poenaru D, De Santis M, Christou NV. Imipenem versus tobramycin-antianaerobe antibiotic therapy in intra-abdominal infections. Can J Surg 1990;33:415-422.
27. Solomkin JS, Dellinger EP, Christou NV, et al. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990;212:581-591.
28. Luke M, Iversen J, Søndergaard J, et al. Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. Eur J Surg 1991;157:397-401.
29. Meller JL, Reyes HM, Loeff DS, et al. One-drug versus two-drug antibiotic therapy in pediatric perforated appendicitis: a prospective randomized study. Surgery 1991;110:764-768.
30. Paakkonen M, Alhava EM, Huttunen R, et al. Piperacillin compared with cefuroxime plus metronidazole in diffuse peritonitis. Eur J Surg 1991;157: 535-537.
31. Schropp KP, Kaplan S, Golladay ES, et al. A randomized clinical trial of ampicillin, gentamicin and clindamycin versus cefotaxime and clindamycin in children with ruptured appendicitis. Surg Gynecol Obstet 1991;172:351-356.
32. Sirinek KR, Levine BA. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet 1991;172(Suppl):30-35.
33. Williams RR, Hotchkin D. Aztreonam plus clindamycin versus tobramycin plus clindamycin in the treatment of intraabdominal infections. Rev Infect Dis 1991;13:S629-S633.
34. Yoshioka K, Youngs DJ, Keighley MR. A randomized prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection. Infection 1991;19:25-29.
35. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-2773.
36. Eckhauser FE, Knol JA, Raper SE, et al. Efficacy of two comparative antibiotic regimens in the treatment of serious intra-abdominal infections: results of a multicenter study. Clin Ther 1992;14:97-109.
37. Berne TV, Yellin AE, Appleman MD, et al. A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. Surg Gynecol Obstet 1993;177(Suppl):18-22.
38. de Groot HG, Hustinx PA, Lampe AS, et al. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1993;32:491-500.
39. Kanellakopoulou K, Giamarellou H, Papadothomakos P, et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993;12:449-453.
40. Niinikoski J, Havia T, Alhava E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993;176:255-261.
41. Polk HC Jr, Fink MP, Laverdiere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. Am Surg 1993;59:598-605.
42. Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a beta-lactamase inhibitor combination for serious intra-abdominal infections. Ann Surg 1993;217:115-121.
43. Yellin AE, Berne TV, Heseltine PN, et al. Prospective randomized study of two different doses of clindamycin admixed with gentamicin in the management of perforated appendicitis. Am Surg 1993;59: 248-255.
44. Barboza E, del Castillo M, Yi A, et al. Clindamycin plus amikacin versus clindamycin plus aztreonam in established intraabdominal infections. Surgery 1994; 116:28-35.
45. Greenberg RN, Cayavec P, Danko LS, et al. Comparison of cefoperazone plus sulbactam with clindamycin plus gentamicin as treatment for intra-abdominal infections. J Antimicrob Chemother 1994;34: 391-401.
46. Hopkins JA, Wilson SE, Bobey DG. Adjunctive antimicrobial therapy for complicated appendicitis: bacterial overkill by combination therapy. World J Surg 1994;18:933-938.
47. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995; 35:139-148.
48. Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995;21:544-550.
49. Dougherty SH, Sirinek KR, Schauer PR, et al. Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. Am Surg 1995;61:297-303.
50. Geroulanos SJ, the Meropenem Study Group. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. J Antimicrob Chemother 1995;36(Suppl A):191-205.
51. Huizinga WKJ, Warren BL, Baker LW, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995;36(Suppl A):179-189.
52. Shyr YM, Lui WY, Su CH, et al. Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections. Chung Hua I Hsueh Tsa Chih-Chinese Med J 1995;56: 102-108.
53. Angerås MH, Darle N, Hamnström K, et al. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Scand J Infect Dis 1996; 28(5):513-518.
54. Berne TV, Yellin AE, Appleman MD, et al. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. J Am Coll Surg 1996;182:403-407.
55. Christou NV, Turgeon P, Wassef R, et al. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. Arch Surg 1996;131:1193-1201.
56. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg 1996;223:303-315.
57. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg 1997;132:1294-1302.
58. Basoli A, Meli EZ, Mazzocchi P, et al. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 1997;29:503-508.
59. Chang DC, Wilson SE. Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Am J Surg 1997;174:284-290.
60. Ciftci AO, Tanyel FC, Büyükpamukçu N, et al. Comparative trial of four antibiotic combinations for perforated appendicitis in children. Eur J Surg 1997;163: 591-596.
61. Kempf P, Bauernfeind A, Müller A, et al. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. Infection 1996;24:473-479.
62. Wilson SE. Results of randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Clin Infect Dis 1997;24(Suppl 2):S197-206.
63. Collins MD, Dajani AS, Kim KS, et al. Comparison of ampicillin/sulbactam plus aminoglycoside vs. ampicillin plus clindamycin plus aminoglycoside in the treatment of intraabdominal infections in children. Pediatr Infect Dis J 1998;17(3 Suppl):S15-S18.
64. Donahue PE, Smith DL, Yellin AE, et al. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Am J Surg 1998;176(Suppl 6A): 53S-61S.
65. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42: 2966-2972.
66. Allo MD, Bennion RS, Kathir K, et al. Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. Am Surg 1999;65:99-104.
67. Ohlin B, Cederberg A, Forssell H, et al. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur J Surg 1999;165:875-884.
68. Zanetti G, Harbarth SJ, Trampuz A, et al. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. Int J Antimicrob Agents 1999; 11:107-113.
69. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000;232:254-256.
70. Röhrborn A, Wacha H, Schöffel U, et al. Coverage of enterococci in community-acquired secondary peritonitis: results of a randomized trial. Surg Infect 2000;1:95-107.
71. Torres AJ, Valladares LD, Jover JM, et al. Cefminox versus metronidazole plus gentamicin in intra-abdominal infections: a prospective randomized controlled clinical trial. Infection 2000;28:318-322.
72. Solomkin JS, Yellin E, Rotstein OD, et al. Results of a double-blind, randomized comparative phase III trial of ertapenem vs. piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg (in press).
73. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996;124:717-725.
74. Hollender LF, Bahnini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother 1989;23: 773-783.
75. de Vries PJ, Verkooyen RP, Leguit P, et al. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990;9:161-168.
76. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214: 543-549.
77. Dellinger EP, Wertz MJ, Meakins JL, et al. Surgical infection stratification system for intra-abdominal infection. Arch Surg 1985;120:21-29.
78. Christou NV, Barie PS, Dellinger EP, et al. Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. Arch Surg 1993;128:193-199.
79. Bohnen JM, Mustard RA, Schouten BD. Steroids, APACHE II score, and the outcome of abdominal infection. Arch Surg 1994;129:33-37.
80. Schoeffel U, Jacobs E, Ruf G, et al. Intraperitoneal micro-organisms and the severity of peritonitis. Eur J Surg 1995;161:501-508.
81. Pacelli F, Doglietto GB, Alfieri S, et al. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg 1996;131:641-645.
82. Ohmann C, Hau T. Prognostic indices in peritonitis. Hepatogastroenterology 1997;44:937-946.
83. Wacha H, Hau T, Dittmer R, et al. Risk factors associated with intraabdominal infections: a prospective multicenter study. Langenbecks Arch Surg 1999;384: 24-32.
84. Hopkins JA, Lee JCH, Wilson SE. Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection. Am Surg 1993;59:791-796.
85. Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996; 23:486-494.
86. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38:1309-1313.
87. Hoogkamp-Korstanje JA. Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections. Infection 1995;23:278-282.
88. Dupont H, Carbon C, Carlet J, The Severe Generalized Peritonitis Study Group. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother 2000;44:2028-2033.
89. Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 1995;118:716-723.
90. Solomkin JS, Flohr AB, Quie PG, et al. The role of Candida in intraperitoneal infections. Surgery 1980;88: 524-530.
91. Calandra T, Bille J, Schneider R, et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989;2(8677):1437-1440.
92. Eggiman P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999;27: 1066-1072.
93. Abele-Horne M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996;24:426-432.
94. Rotstein OD, Pruett TL, Simmons RL. Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit. Can J Surg 1986;29: 247-250.
95. Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998;22:158-163.
96. Solomkin JS. Antibiotic resistance in postoperative infections. Crit Care Med 2001;29(Suppl):N97-N99.